Drug intelligence / Profile preview

TRX319

Development stage: Phase 2
Lead developer: Tr1X
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TRX319 is an allogeneic polyclonal chimeric antigen receptor (CAR) T regulatory cell (Treg) therapy leveraging Type 1 regulatory T (Tr1) cells. It is being developed by Tr1X for the treatment of multiple B-cell mediated autoimmune diseases. The therapy is designed to target CD19, thereby inhibiting B cells, while also modulating T cell responses and reducing inflammation. This dual mechanism aims to restore immune tolerance and address the underlying causes of autoimmune disorders. As of early 2025, TRX319 is in IND-enabling studies and has not yet entered clinical trials[1][2][5][8].

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on TRX319.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRX319.

Explore the full profile